Johnson & Johnson stock holds steady on its healthcare scale

Johnson & Johnson (ISIN US4781601046) is a diversified healthcare company with operations in pharmaceuticals and medical technology, and it trades on the New York Stock Exchange as JNJ. The company's broad mix gives investors exposure to drug development, devices, and global healthcare demand.

Business scope

Johnson & Johnson's portfolio spans prescription medicines and medical technologies, which makes its earnings profile less dependent on a single product line than many peers. That diversification is the central structural feature of the stock.

Market context

As one of the largest components of the US healthcare universe, Johnson & Johnson often serves as a defensive benchmark inside the sector. Its scale and balance sheet are part of the appeal for investors who want steadier exposure to healthcare than a pure-growth name typically offers.

Representative product

Stelara is one of Johnson & Johnson's best-known medicines, and it illustrates how the company combines branded pharmaceuticals with a wider medical franchise. The product mix matters because revenue concentration tends to be lower when a company can lean on multiple treatment categories.

Stock context

Johnson & Johnson stock last traded at $0.00 as of July 10, 2026, 1:55 p.m. ET. The figure is included here only as a format reference for the article structure.